SEC Comment Letter 0000000000-24-001426 to BridgeBio Oncology Therapeutics, Inc. (BBOT)
BridgeBio Oncology Therapeutics, Inc.
Date: Feb. 6, 2024 · CIK: 0001869105 · Accession: 0000000000-24-001426
AI Filing Summary & Sentiment
File numbers found in text: 333-276591
Show Raw Text
United States securities and exchange commission logo
February 6, 2024
Bihua Chen
Chief Executive Officer
Helix Acquisition Corp. II
200 Clarendon Street, 52nd Floor
Boston, MA 02116
Re:Helix Acquisition Corp. II
Amendment No. 1 to Registration Statement on Form S-1
Filed February 2, 2024
File No. 333-276591
Dear Bihua Chen:
We have reviewed your amended registration statement and have the following comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Amendment No. 1 to Registration Statement on Form S-1 filed February 2, 2024
Risk Factors, page 32
1.We note your investment company risk factors beginning on page 41. Please disclose that
if you are found to be operating as an unregistered investment company, you may be
required to change your operations, wind down your operations, or register as an
investment company under the Investment Company Act. Also include disclosure with
respect to the consequences to investors if you are required to wind down your operations
as a result of this status, such as the losses of the investment opportunity in a target
company, and any price appreciation in the combined company. Please confirm that if
your facts and circumstances change over time, you will update your disclosure to reflect
how those changes impact the risk that you may be considered to be operating as an
unregistered investment company.
FirstName LastNameBihua Chen
Comapany NameHelix Acquisition Corp. II
February 6, 2024 Page 2
FirstName LastName
Bihua Chen
Helix Acquisition Corp. II
February 6, 2024
Page 2
Please contact Paul Cline at 202-551-3851 or Isaac Esquivel at 202-551-3395 if you have
questions regarding the financial statements and related matters. Please contact Ronald (Ron) E.
Alper at 202-551-3329 or Pam Howell at 202-551-3357 with any other questions.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction
cc: Joel Rubinstein